1D09C3

Cat. No.: HY-P991590: Data Sheet
FAQs
Technical Support

1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL).

For research use only. We do not sell to patients.

1D09C3 Chemical Structure

CAS No. : 791073-97-7

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All MHC Isoform Specific Products:

View All Isoforms

MHC I MHC II

View All JNK Isoform Specific Products:

View All Isoforms

JNK1 JNK2 JNK3 JNK

Biological Activity
Purity & Documentation
References
Customer Review

Description

Species Reactivity

Human

IC₅₀ & Target

HLA-DR β

In Vitro

1D09C3 (2.5 µg/ mL, 24 h) significantly reduces cell countings and cell survival in HLA-DR⁺, but not HLA-DR^- cell lines^[1][2].

1D09C3 (0.1-10 µg/ mL, 4-24 h) induces a potent time- and dose-dependent death of JVM-2 and GRANTA-519 cells^[1].

1D09C3 (10 µg/ mL, 4-24 h) induces cell apoptosis through a caspase-independent pathway in JVM-2 and GRANTA-519 cells^[1].

1D09C3 (10 µg/ mL, 5-240 min) induces mitochondrial depolarization and generation of ROS in JVM-2 and GRANTA-519 cells^[1].

1D09C3 (10 µg/ mL, 0.5-4 h) induces cell death involving activation of the JNK^[1].

1D09C3 (2.5 µg/ mL, 4 h) induces cell death B-CLL cell death^[1][3].

1D09C3 (10 µg/ mL, 48 h) reduces cell counts by 20% for activated T cells and by 50% for resting and activated B cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	HLA-DR+ cell lines JVM-2 and GRANTA-519 and the HLA-DR cell line SU-DHL-1
Concentration:	2.5 µg/ mL
Incubation Time:	24 h
Result:	Reduced the absolute number of viable cells by 3-fold and 48-fold, and the survival of tumor cells by 33-fold and 25-fold for JVM-2 and GRANTA-519, respectively

Western Blot Analysis^[1]

Cell Line:	JVM-2 and GRANTA-519 cells
Concentration:	10 µg/mL
Incubation Time:	4, 18 and 24 h
Result:	Showed no significant change of caspase-8, 9, 3 and RARP.

Western Blot Analysis^[1]

Cell Line:	GRANTA-519 cells
Concentration:	10 μg/mL
Incubation Time:	0.5, 1, 2 and 4 h
Result:	Upregulated the levels of JNK in mitochondrial and AIF in cytosolic.

In Vivo

1D09C3 (0.01-6 mg/mouse, i.v.) significantly increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	JVM-2 (1 x 10⁶)cells xenograft mice models (NOD/SCID mice, 6-8 weeks)^[1]
Dosage:	0.01 mg/mouse (day 4), 0.1 mg/mouse (day 4)
Administration:	Intravenous injection
Result:	Resulted in a 20% overall survival with a median survival time of 64 days.

Animal Model:	JVM-2 (0.25 x 10⁶) cells xenograft mice models (NOD/SCID mice, 6-8 weeks)^[1]
Dosage:	3 x 1 mg/mouse (day 4, 7, 9) and 1 mg/mouse (day 4) for treatment of early-stage disease; 6 x 1 mg/mouse at 48-hour intervars starting onday 15 for treatment of advanced-stage disease
Administration:	Intravenous injection
Result:	Resulted in a 100% survival at dose up to 3 mg/mouse, and a 42% overall survival with a median survival of 99 days.

Animal Model:	GRANTA-519 cells and KMS-11 cells xenograft mice models (NOD/SCID mice, 6-8 weeks)^[1][2][3]
Dosage:	3 x 1 mg mouse (days 1, 4, and 7) for treatment of early-stage disease and 6 x 1 mg/mouse at 48-hour intervars starting onday 7 for treatment of advanced-stage disease
Administration:	Intravenous injection
Result:	Resulted in a significant increase of median survival (108 days), with 27% mice being alive and disease-free at the end of the 120-day observation period

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

CAS No.

791073-97-7

SMILES

N/A

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Carlo-Stella C, et al. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2006 Feb 1;66(3):1799-808. [Content Brief]

[2]. Carlo-Stella C, et al. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Res. 2007 Apr 1;67(7):3269-75. [Content Brief]

[3]. Nagy ZA, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002 Aug;8(8):801-7. [Content Brief]

1D09C3 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

1D09C3791073-97-7MHCApoptosisJNKReactive Oxygen Species (ROS)Major Histocompatibility Complexc-Jun N-terminal kinaseHLA-DRCancerROSJNK,CLLInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *